Regeneron Pharmaceuticals, Inc.
- Open
- 782.44
- Day high
- 802.49
- Day low
- 779.08
- Prev close
- 794.19
- Volume
- 752K
- Mkt cap
- $82.3B
- P/E (TTM)
- 19.1
- EPS (TTM)
- $41.88
- P/B
- 2.6
- P/S
- 5.3
- Yield
- 0.46%
- Per share
- $3.70
- ▼Insiders net selling -$1.1M over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions mixed (13F)
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare company listed on NASDAQ. The stock is up 38% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
Regeneron Pharmaceuticals, Inc. (REGN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 11 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
REGN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $10.16 | $14.29 | +40.6% | $4.3B | +12.4% |
| Apr 29, 2026 | $8.91 | $9.47 | +6.3% | $3.6B | +3.6% |
| Jan 30, 2026 | $10.74 | $11.44 | +6.5% | $3.9B | +1.9% |
| Aug 1, 2025 | $8.43 | $12.89 | +52.9% | $3.7B | +11.8% |
| Feb 4, 2025 | $11.23 | $12.07 | +7.5% | $3.8B | +1.4% |
| Oct 31, 2024 | $11.69 | $12.46 | +6.6% | $3.7B | +1.4% |
| Aug 1, 2024 | $10.60 | $11.56 | +9.0% | $3.5B | +4.9% |
| May 2, 2024 | $10.18 | $9.55 | -6.1% | $3.1B | -2.8% |
| Feb 2, 2024 | $10.73 | $11.86 | +10.5% | $3.4B | +4.3% |
| Nov 2, 2023 | $10.69 | $11.59 | +8.5% | $3.4B | +5.4% |
| Aug 3, 2023 | $9.76 | $10.24 | +4.9% | $3.2B | +6.2% |
| May 4, 2023 | $9.17 | $10.09 | +10.0% | $3.2B | +6.7% |
REGN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | LAROSA JOSEPH Jofficer: EVP General Counsel and Secret | Tax | 9,019 | $830.15 |
| Aug 21, 2026 | LAROSA JOSEPH Jofficer: EVP General Counsel and Secret | Option | 12,282 | $381.92 |
| Aug 20, 2026 | Fenimore Christopher R.officer: EVP Finance CFO | Tax | 4,599 | $813.47 |
| Aug 20, 2026 | Fenimore Christopher R.officer: EVP Finance CFO | Option | 6,283 | $381.92 |
| Aug 12, 2026 | Zoghbi Huda Ydirector | Sell | 800 | $800.00 |
| Aug 12, 2026 | Guarini Kathryndirector | Option | 400 | $719.37 |
| Aug 12, 2026 | Guarini Kathryndirector | Sell | 400 | $800.00 |
| Aug 12, 2026 | Zoghbi Huda Ydirector | Option | 800 | $376.69 |
| Jul 7, 2026 | RYAN ARTHUR Fdirector | Sell | 200 | $650.15 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 4 | $707.40 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 7 | $706.74 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 1 | $712.09 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 15 | $702.46 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 14 | $705.56 |
| May 4, 2026 | RYAN ARTHUR Fdirector | Sell | 2 | $710.87 |
Source: REGN SEC Form 4 filings, latest Aug 21, 2026. For informational purposes only — not investment advice.
See the full REGN insider & 13F page →Regeneron Pharmaceuticals, Inc. company profile
Overview
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company went public in 1991 and has evolved from a research-focused startup into one of the world's premier biotechnology companies. Regeneron discovers, develops, manufactures, and commercializes innovative medicines for serious diseases across multiple therapeutic areas including ophthalmology, immunology, oncology, and rare diseases. The company is known for its proprietary drug discovery platforms and has built a portfolio of blockbuster medicines that serve patients worldwide.
Business
Regeneron operates in the biotechnology sector, focusing on developing and commercializing prescription medicines for serious medical conditions. The biotechnology industry involves using biological processes and living organisms to develop pharmaceutical products, which typically require extensive research, clinical trials, and regulatory approval before reaching patients. The company's business is organized around several key therapeutic areas and products: Ophthalmology Franchise (~25% of revenue): Regeneron's flagship product is EYLEA (aflibercept), an injection treatment for various eye diseases including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Age-related macular degeneration is a leading cause of vision loss in older adults, while diabetic eye diseases affect millions of people with diabetes. The company has also launched EYLEA HD, a higher-dose formulation that allows for less frequent dosing. These medicines work by blocking proteins that cause abnormal blood vessel growth and leakage in the eye, which can lead to vision loss. Immunology and Inflammatory Diseases (~45% of revenue): Dupixent (dupilumab) is Regeneron's fastest-growing product, developed in partnership with Sanofi. This injectable medicine treats multiple conditions driven by Type 2 inflammation, including atopic dermatitis (severe eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and chronic obstructive pulmonary disease (COPD). The drug works by blocking specific proteins that drive inflammatory responses in these conditions. Oncology (~5% of revenue): Libtayo (cemiplimab) is an immunotherapy treatment for certain types of skin cancer and lung cancer. It works by helping the immune system recognize and attack cancer cells. The company also has several experimental cancer treatments in development, including bispecific antibodies that can simultaneously target cancer cells and activate immune responses. Other Products (~25% of revenue): This includes Praluent for high cholesterol, Kevzara for rheumatoid arthritis, treatments for rare diseases like Ebola virus infection, and various other specialized medicines. The company also received significant revenue from COVID-19 antibody treatments during the pandemic.
Revenue model
Regeneron generates revenue primarily through direct product sales of its approved medicines to healthcare providers, hospitals, and specialty pharmacies. The company operates under several different business models depending on the product: Direct Sales Model: For products like EYLEA in the United States, Regeneron retains full commercial rights and receives 100% of net sales revenue. These medicines are sold to retinal specialists, hospitals, and ambulatory surgery centers that administer the injections to patients. Partnership Revenue Sharing: For Dupixent, Regeneron has a global collaboration with Sanofi where they share development costs and split profits. In the U.S., Regeneron records its share of collaboration profits, while outside the U.S., Sanofi leads commercialization and pays Regeneron royalties and profit-sharing payments. Royalty and Milestone Payments: The company receives royalties from partners who license its technologies or co-develop products. These provide ongoing revenue streams from successful products without requiring Regeneron to fund all commercialization activities. Several factors significantly impact Regeneron's profitability margins. Competitive pressure in the ophthalmology market from newer treatments like Roche's Vabysmo has begun affecting EYLEA sales growth. Patent expiration represents a major future risk, as biosimilar competition could dramatically reduce prices once patents expire. Regulatory approval timelines affect when new products can generate revenue, with recent delays in product approvals impacting near-term growth expectations. Manufacturing costs and capacity influence margins, particularly as the company invests over $7 billion in new U.S. manufacturing facilities. Pricing pressure from payers and government entities continues to constrain price increases across the pharmaceutical industry. Patient assistance program funding can temporarily impact sales, as seen with EYLEA when foundation funding gaps reduced patient access. Currency fluctuations affect international revenue when converted to U.S. dollars, while research and development investment levels directly impact operating margins as the company maintains one of the industry's most robust pipelines.
Competitive moat
Regeneron possesses several significant competitive advantages that create a substantial economic moat. The company's proprietary drug discovery platforms, including VelociGene for creating genetically modified mice and VelocImmune for generating human antibodies, provide unique capabilities that competitors cannot easily replicate. These platforms have enabled the company to discover and develop multiple breakthrough medicines more efficiently than traditional approaches. The company's deep scientific expertise and research capabilities represent another key moat element. Regeneron has built world-class capabilities in areas like antibody engineering, genetics, and immunology, supported by a team of renowned scientists and substantial R&D investment. This expertise allows the company to tackle complex diseases that others cannot address effectively. Strong intellectual property protection provides temporary but significant competitive barriers. Patents on key products like EYLEA and Dupixent prevent generic competition for years, allowing the company to maintain premium pricing and invest in future innovation. However, Regeneron faces meaningful competitive threats. Biosimilar competition will eventually erode revenues from current blockbuster products as patents expire. Large pharmaceutical companies with greater resources continue to invest heavily in competing treatments, as evidenced by Roche's Vabysmo gaining market share against EYLEA. Emerging biotechnology companies with novel approaches could disrupt existing treatment paradigms, while technological advances in areas like gene therapy and cell therapy could potentially replace traditional antibody-based treatments. The strength of Regeneron's moat varies by therapeutic area. In ophthalmology, the company faces increasing competition but maintains advantages through its established relationships with retinal specialists and superior clinical data. In immunology, Dupixent's broad efficacy across multiple Type 2 inflammatory diseases creates a strong competitive position, though this could be challenged by next-generation treatments. The company's overall moat remains robust in the medium term but requires continuous innovation and successful pipeline execution to maintain long-term competitive advantages.
Risks & safety
Regeneron demonstrates a strong financial safety profile with multiple protective factors: **Overall Assessment**: The company maintains excellent financial health with minimal solvency risk and strong cash generation capabilities. **Cash and Liquidity Position**: - Cash and short-term investments: $3.1 billion as of Q1 2025 - Total current assets: $17.6 billion vs. current liabilities of $3.6 billion - Current ratio of 4.9x indicates very strong liquidity - Free cash flow generation of $774 million in Q1 2025 alone **Debt and Solvency Metrics**: - Very low debt-to-equity ratio of 0.09x - Minimal financial leverage with total liabilities of only $8.2 billion vs. $37.5 billion in assets - Strong interest coverage with minimal debt service requirements - No meaningful solvency concerns given strong balance sheet **Valuation Considerations**: - P/E ratio of 20.9x appears reasonable for a growing biotech company - EV/EBITDA of 16.2x reflects premium valuation but justified by growth prospects - Price-to-book ratio of 2.3x indicates moderate valuation relative to tangible assets - Graham number analysis suggests fair value around $217, indicating current premium pricing **Other Factors**: - Diversified revenue base across multiple products reduces concentration risk - Strong pipeline with 45+ clinical-stage programs provides future growth options - Established partnerships with major pharmaceutical companies provide additional stability - Regulatory approval delays present near-term execution risks but don't threaten fundamental business model
Recent development
Over the past few years, Regeneron has executed several strategic initiatives to diversify its portfolio and strengthen its competitive position. The company successfully launched EYLEA HD, a higher-dose formulation of its flagship eye medicine that allows patients to receive injections less frequently. This launch has gained strong physician adoption and now represents approximately 20% of combined EYLEA sales, helping to defend against competitive pressure from newer treatments. In immunology, Regeneron has significantly expanded Dupixent's approved indications, adding chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria, and preparing for potential approval in bullous pemphigoid. This expansion strategy has driven Dupixent to become the company's largest revenue contributor, with global sales exceeding $3.7 billion quarterly and serving over one million patients worldwide across seven approved indications. The company has made substantial investments in oncology pipeline development, advancing multiple bispecific antibody programs including linvoseltamab for multiple myeloma and odronextamab for follicular lymphoma. These next-generation cancer treatments are designed to simultaneously target cancer cells and activate immune responses, potentially offering superior efficacy compared to existing therapies. Regeneron has also entered new therapeutic areas, including obesity treatment development with a unique approach focused on preserving muscle mass during weight loss by targeting myostatin and Activin A pathways. The company is developing Factor XI antibodies for anticoagulation, potentially addressing a large market with improved safety profiles compared to existing blood thinners. The company initiated its first-ever dividend program in 2024, paying $0.88 per share quarterly, while also authorizing $3 billion in additional share repurchases. This capital allocation strategy reflects management's confidence in future cash flows and provides more flexibility in returning capital to shareholders. Additionally, Regeneron is investing over $7 billion in new U.S. manufacturing and R&D facilities to support future growth and reduce dependence on contract manufacturers following recent regulatory delays.
REGN company profile · for informational purposes only — not investment advice.
Track REGN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free